Skip to main content

Table 1 Comparison of patient background and correlation coefficient +0.4 < group and correlation coefficient + 0.4 group

From: Long-term exposure to pemetrexed induces chronic renal dysfunction in patients with advanced and recurrent non-squamous cell lung cancer: a retrospective study

  All, N = 90 r+0.4<, N = 49 r+0.4, N = 41 P  
Gender, N (%) Men / women 56 (62) / 34 (38) 31 (63) / 18 (37) 25 (61) / 16 (39) 0.82a)
Age, median (interquartile range)   68 (63, 74) 68 (62, 73) 68 (63, 74) 0.51b)
Histological type, N (%) adenocarcinoma 86 (96) 47 (96) 39 (95) 0.62a)
malignant pleural mesothelioma 4 (4) 2 (4) 2 (5)  
Stage, N (%) IIIA and IIIB 27 (30) 17 (35) 10 (24) 0.56a)
IV and recurrence 63 (70) 32 (65) 31 (76)  
Performance status, N (%) 0 and 1 85 (95) 45 (92) 40 (97) 0.42a)
2 and 3 5 (5) 4 (8) 1 (3)  
Smoking history, N (%) no smoking and current 69 (77) 34 (69) 35 (85) 0.07a)
never 21 (23) 15 (31) 6 (15)  
Complications, N (%)
 Diabetes YES / NO 18 (20) / 72 (80) 7 (14) / 42 (86) 11 (27) / 30 (73) 0.14a)
 Hypertension YES / NO 37 (41) / 53 (59) 19 (39) / 30 (61) 18 (44) / 23 (56) 0.62a)
 Hyperlipemia YES / NO 9 (10) / 81 (90) 4 (8) / 45 (92) 5 (12) / 36 (88) 0.39a)
Body surface area (m2), median (interquartile range) 1.60 (1.48, 1.72) 1.63 (1.49, 1.79) 1.59 (1.46, 1.68) 0.33c)  
eGFR (ml/min/1.73m2), median (interquartile range) 82 (71, 96) 88 (76, 99) 76 (65, 89) 0.99b)
Estimated Ccr (ml/min), median (interquartile range) 61 (53, 71) 65 (57, 73) 58 (47, 64) 0.64b)  
eGFR45, <60 (ml/min/1.73m2), N (%) 11 (12) 4 (8) 7 (17) 0.20a)  
Scr (g/dl), median (interquartile range) 0.6 (0.6, 0.8) 0.6 (0.5, 0.8) 0.7 (0.6, 0.8) 0.82c)  
Chemotherapy, N (%) CBDCA+PEM+BEV 72 (80) 37 (76) 35 (85) 0.24a)
CBDCA+PEM 18 (20) 12 (24) 6 (15)  
Concomitant drug, N (%)
 NSAIDs YES / NO 18 (20) / 72 (80) 15 (31) / 34 (69) 3 (7) / 38 (93) < 0.01a)
 ARB YES / NO 26 (29) / 64 (71) 12 (24) / 37 (76) 14 (34) / 27 (66) 0.31a)
 ACEI YES / NO 3 (3) / 87 (97) 0 (0) / 49 (100) 3 (7) / 38 (93) 0.09a)
 PPI YES / NO 30 (33) / 60 (67) 16 (33) / 33 (67) 14 (34) / 27 (66) 0.88a)
Total number of treatments, median (interquartile range) 9 (6, 13) 11 (8, 14) 8 (6, 11) < 0.01b)  
  1. Ccr creatinine clearance, Scr serum creatinine, CBDCA carboplatin, PEM pemetrexed, BEV bevacizumab, NSAIDs non-steroidal anti-inflammatory drugs, ARB angiotensin II receptor antagonist, ACEI angiotensin converting enzyme inhibitor, PPI proton pump inhibitor
  2. a)Fisher’s exact test
  3. b)Student’s t test
  4. c)Mann-Whitney U test